Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples